Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.

AIM

To structurally modify our existing cholic acid (CA)-based telodendrimer (TD; PEG-CA) for effective micellar nanoencapsulation and delivery of the US FDA-approved members of taxane family.

MATERIALS & METHODS: Generation of hybrid TDs was achieved by replacing four of the eight CAs with biocompatible organic moieties using solution-phase peptide synthesis. Drug loading was done using the standard evaporation method.

RESULTS

Hybrid TDs can generate micelles with narrow size distributions, low critical micelle concentration values (1-6 μM), better hematocompatibility and lack of in vitro cytotoxicity.

CONCLUSION

Along with PEG-CA, CA-based hybrid nanoplatform is the first of its kind that can stably encapsulate all three FDA-approved taxanes with nearly 100% efficiency up to 20% (w/w) loading.